A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.

Lyndon Marc EvansLinda MellbinPierre JohansenJack LawsonAbby PaineAnna Sandberg

Published in: Endocrinology, diabetes & metabolism (2021)

This study demonstrated a statistically significant lower risk of 3P MACE for s.c. semaglutide versus placebo, in a population with lower prevalence of pre-existing CVD than that in the pre-specified primary analysis in SUSTAIN 6. Reduction in 3P MACE with s.c. semaglutide was greater than with dulaglutide, although not statistically significant.

Keyphrases

cardiovascular disease
risk factors
type diabetes
randomized controlled trial
metabolic syndrome
coronary artery disease
cardiovascular events
study protocol
open label